189 Improvement in systemic hemodynamics after mars is associated with a decrease in vasoactive substances in patients with acute on chronic liver failure (AOCLF): Results of a randomised trial

Laleman, Wim; Nevens, Frederik; Wilmer, A.; Evenepoel, Pieter; Pelt, Jos van; Fevery, Johan

doi:10.1016/s0168-8278(04)90189-4

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Elimination of bilirubin and other albumin‐bound substances during ECAD has been reported by several authors 27–31. However, this is the first report of an improvement of albumin binding function by the elimination of albumin ligands during albumin dialysis.…”

Section: Discussionmentioning

confidence: 61%

Overall and cause‐specific survival for patients undergoing lobectomy, near‐total, or total thyroidectomy for differentiated thyroid cancer

et al. 2011

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 61%

Overall and cause‐specific survival for patients undergoing lobectomy, near‐total, or total thyroidectomy for differentiated thyroid cancer

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Elimination of bilirubin and other albumin-bound substances during ECAD has been reported by several authors. [27][28][29][30][31] However, this is the first report of an improvement of albumin binding function by the elimination of albumin ligands during albumin dialysis.…”

Section: Discussionmentioning

confidence: 86%

Improvement of impaired albumin binding capacity in acute-on-chronic liver failure by albumin dialysis

et al. 2008

View full text Add to dashboard Cite

Extracorporeal albumin dialysis (ECAD) enables the elimination of albumin bound substances and is used as artificial liver support system. Albumin binding function for the benzodiazepine binding site specific marker Dansylsarcosine was estimated in plasma samples of 22 patients with cirrhosis and hyperbilirubinaemia (ECAD: n ϭ 12; control: n ϭ 10) during a period of 30 days in a randomized controlled clinical ECAD trial. Albumin Binding Capacity (ABiC) at baseline was reduced to 31.8% (median; range 24%-74%) and correlated to the severity of liver disease. Within two weeks a significant improvement of ABiC and a reduction of the albumin bound markers bilirubin and bile acids were observed in the ECAD group. During single treatments a significant decrease of albumin bound substances (bilirubin and bile acids) as well as an increase in ABiC was observed. In the control group, baseline ABiC was significantly lower in patients who died during study period (34.2% vs. 41.7%; P Ͻ 0.028), whereas no significant differences were observed for CHILD, coagulation factors, albumin, bile acids nor bilirubin. At baseline 13 patients had a severely impaired ABiC (Ͻ40%), improvement of ABiC was more frequent in the ECAD group (5/6) than in the SMT group (2/7). Reduced albumin binding function is present in decompensated liver failure and is related to severity and 30 day survival. ABiC can be improved by ECAD. The beneficial effect of this treatment may be related to the improvement of albumin binding function more than to the elimination of specific substances. Characterization of albumin function by the ABiC test may help to evaluate different liver support systems and other therapeutic measures.

show abstract

189 Improvement in systemic hemodynamics after mars is associated with a decrease in vasoactive substances in patients with acute on chronic liver failure (AOCLF): Results of a randomised trial

Cited by 2 publications

References 0 publications

Overall and cause‐specific survival for patients undergoing lobectomy, near‐total, or total thyroidectomy for differentiated thyroid cancer

Overall and cause‐specific survival for patients undergoing lobectomy, near‐total, or total thyroidectomy for differentiated thyroid cancer

Improvement of impaired albumin binding capacity in acute-on-chronic liver failure by albumin dialysis

Contact Info

Product

Resources

About